Insights Accelerated
Meet our Accelerators - Patricia Beckmann
From Uppsala postdoc to co-inventor of the blockbuster drug Enbrel — Patricia Beckmann's career has been anything but a straight line. In this interview, she reflects on lessons learned from failures and shelved successes, and why she believes a Seattle–Sweden life science exchange could propel both ecosystems forward.
At BIO 2026, partnerships moved beyond the deal.
Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.
The Crown Jewel Test
Why did fewer meetings at BIO 2026 deliver more than a packed calendar ever did? In a recent interview AOP Health's Eszter Kormann shares her "crown jewel" philosophy of sourcing — why fair beats cheap, what happens after the signature, and why the scarcest resource in dealmaking is conviction.
New Players Are Reshaping Life Science Financing
A recent pitch night hosted by Cancerfonden together with VILDA offered a glimpse of a broader shift taking place in life science financing.
Backtracking from the Endgame
AnaCardio is using its CEO’s experience on both sides of pharma partnering to shape a global Phase 2b for AC01, its oral treatment candidate for heart failure.
The Conversations That Keep Going
What makes some conversations continue long after a conference ends — and even turn into signed deals within weeks? Venture Road's journeys through California, Stockholm and the UK reveal what happens when the right people actually meet. Next stop: Venture Bridge during Nobel Week. Read on to find out why participants keep coming back.
Biotech Conference Approaching - Should I fill up my Dance Card?
Is your partnering conference calendar full — or full of the right meetings? This witty take on biotech business development weighs precision matchmaking against speed-dating-style volume, and lands on a smarter third way. Before you book another dance card, read this article.
Meet our accelerators: Ragnar Strigård & Njord
Recent interview with Ragnar Strigård explores how his accelerator model helps life science founders transform high‑potential research into fundable, scalable companies.
Beyond the Science: Decoding the "Globally Street Smart" Approach to Negotiation
In a recent interview, Helena shared her perspective on why authenticity, a tolerance for friction, and the ability to "read the room" from a macro perspective are the tools to thrive in negotiations.
The Hard Middle of Biotech
Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.
Strategic Partnership: Iconovo’s Long-Term Collaboration with Lonza
How does a small inhalation specialist become a trusted global player? Iconovo’s Anders Månsson shares why deep, strategic partnerships with leaders like Lonza can transform both technology access and investor confidence.
Driven by Purpose: Voices from the Swedish Pavilion at BIO International 2026
As this year’s BIO International Convention embraced the theme Driven by Purpose, Ventures Accelerated sent a flying reporter to the Swedish Pavilion to meet the innovators behind Sweden’s life science companies.
Evolving Landscape of Global Healthcare Partnerships
Kristel Sauter talks about the connection dynamics in BIO-International 2026, as a global gathering point and shares insights on the latest acquisitions trends and partnership potential.
Modelling the future of Biotech Operations
Biotech’s future won’t be won by a single business model. In this editorial, Anders Månsson breaks down the strengths and weaknesses of asset, platform, and service models—and argues that the real winners will be hybrids that blend all three to stay financeable, scalable, and resilient in tougher markets.
OnDosis continues to drive the conversation on individualized dosing in ADHD
Achieving the right dose remains one of the biggest challenges in ADHD treatment. Discover how individualized dose optimization could improve treatment continuity, patient adherence, and long-term outcomes.
The Hidden Value of Nordic Life Science Innovation
Many Nordic life science companies have world-class science, yet struggle to attract the attention they deserve. In this exclusive Venture Road UK conversation, investor Altar Munis reveals what truly matters to UK investors—and why the right story can be just as important as the science itself.
Connecting the Golden Triangle and Nordics: Venture Road UK 2026 Kick Off
Discover how leading players from the UK and Nordic life sciences ecosystems are joining forces to accelerate innovation and advance the future of Precision Health.
Targeted Cancer Therapies with Avacta: From Scientific Story to Patient Impact
Last Thursday during Venture Road UK, companies from across the Nordics and the UK pitched in front of a mixed audience of investors and industry partners. Our warm congratulations to the winner of the pitch session, Christina Coughlin, CEO of Avacta, who is working on targeted cancer therapy delivery to improve efficacy while reducing side effects for patients.
Beyond the Convention Floor: Positioning Nordic Life Science Leaders for BIO International 2026
As BIO International 2026 approaches, standing out requires more than breakthrough science. Discover how Ventures Accelerated helps Nordic life science companies transform visibility into strategic partnerships through targeted positioning, exclusive interviews, and global outreach.
Beyond Science Excellence: Using IP and Strategy to Reach Successful Life Science Exits
Through our new partnership with AWA Sweden, we explore how strategic IP management can strengthen valuation, support funding, and prepare companies for successful partnerships and exits.